The pre-event planning material for the BIO 2008 conference is pouring in fast and furious. (Do you plan to attend? Would you like to meet? Please contact me to arrange arubenstein@rnaventures.com). So whilst perusing the Product Focus Zone publication I was incredibly excited to see BaroFold (Boulder) highlighted in the Protein Therapeutics chapter. Jeff Cleland, [...]

• 387http://clsdf.com/2008/05/it%e2%80%99s-starting-to-look-a-lot-like-bio%e2%80%a6/It%E2%80%99s+Starting+to+Look+a+lot+Like+BIO%E2%80%A62008-05-05+14%3A29%3A00admin

BaroFold continues to march, achieving milestone after milestone. Congratulations are in order now for striking a process development and cGMP manufacturing agreement for their lead compound BaroFeron™ (interferon beta-1b) with Avecia Biologics. Avecia will incorporate BaroFold’s PreEMT™ hydrostatic pressure technology which enables improved, safer, proprietary protein therapeutics, providing product life-cycle extensions and creating new protein [...]

• 242http://clsdf.com/2007/10/baroferon%e2%84%a2-finds-manufacturing-home/BaroFeron%E2%84%A2+Finds+Manufacturing+Home2007-10-22+18%3A25%3A00admin

Last week was the right time at the right place for a meeting at the beautiful new BaroFold offices where I was afforded an opportunity to watch a doe enjoy an afternoon snack of some apples right off the tree.

• 206http://clsdf.com/2007/08/right-place-at-the-right-time/Right+Place+at+the+Right+Time2007-08-21+16%3A55%3A00admin

Among the most common difficulties bio-pharma is faced with when producing recombinant therapeutic proteins is that of protein clumping or aggregation. Such protein aggregation may result in adverse events in patients, limited effectiveness, and a reduction in production yields, at times by as much as 50%, proving to be an incredible cost center. BaroFold, Inc. [...]

• 12View 1 Comment...http://clsdf.com/2005/06/protein-origami-%e2%80%93-barofold-style/Protein+Origami+%E2%80%93+BaroFold+Style2005-06-27+02%3A43%3A00admin